(Tulsa,Okla.)  – On Friday, February 21, a team of Oklahoma Heart Institute (OHI) physicians, led by Drs. Kamran Muhammad, Wayne Leimbach Jr. and Paul Kempe performed the first three successful commercial Transcatheter Aortic Valve Replacement (TAVR) procedures in Oklahoma using the recently FDA-approved Medtronic CoreValve.

    The Medtronic CoreValve transcatheter heart valve was FDA approved in January of this year.  The CoreValve device allows for a broader range of treatment options for patients living with severe aortic stenosis that are poor candidates for open-heart surgery for valve replacement.  It is delivered through a smaller delivery catheter and is available in a greater number of valve sizes, as compared to the first generation transcatheter heart valve system that has been available since 2011.

    “By bringing this new technology to our center, we continue to offer the most versatile and comprehensive valve therapy program in Oklahoma” said Kamran Muhammad, MD, interventional cardiologist and director of the TAVR program at Oklahoma Heart Institute. “There is no doubt that this will allow us to offer life-saving treatment to a greater number of patients with severe aortic stenosis who previously had no other option.”

TAVR is a minimally invasive, life-saving procedure for patients with aortic stenosis who would be considered high a risk for traditional open heart procedures. Aortic stenosis affects the main valve of the heart. In late stages of the disease, the valve does not fully open, causing the heart to work harder. Eventually, the heart’s muscles weaken, increasing the patient’s risk of heart failure and death.

    The mission of Oklahoma Heart Institute (OHI) is to offer high-quality care and innovative technology and procedures to ensure patients have access to world-class cardiovascular care close to home. The early adoption of the CoreValve technology is another example of OHI’s dedication to its mission.

“Oklahoma Heart Institute is among the first ten centers in the country to offer the CoreValve commercially, the first center in Oklahoma to use this device commercially and the only center in Tulsa which has this technology available,” said Dr. Muhammad. “We are proud to be one of the first programs to offer our patients the latest technology for aortic valve replacement. Those diagnosed with severe aortic stenosis often face debilitating side effects and decreased life expectancies. The introduction of CoreValve in our community will allow us to save more lives.”

Since performing Tulsa’s first TAVR procedure in May 2012, Oklahoma Heart Institute’s TAVR program is the premier program of its kind in the region with the most experience and superior outcomes. Today, OHI offers transfemoral, transapical, transaortic and subclavian access transcatheter aortic valve replacement procedures, performed in the state-of-the-art hybrid cardiac catheterization laboratory.


To learn more about Oklahoma Heart Institute’s Transcatheter Aortic Valve Replacement Program, please visit www.oklahomaheart.com/tavr. To refer patients for TAVR at OHI, please call 918-592-0999.